Portola Pharmaceuticals Inc Conference Call on Bevyxxa (betrixaban) Approval
Llamada en conferencia Portola Pharmaceuticals Inc
Portola Pharmaceuticals Inc Conference call or earnings call will be held on 23-jun-2017 During the earnings conference call's session Portola Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact Portola Pharmaceuticals Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. We are advancing our three wholly-owned compounds using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of our potentially life-saving therapies. Two of these compounds were discovered through our internal research efforts and one was discovered by Portola scientists during their time at a prior company. Our Phase 3 programs address significant unmet medical needs in the area of thrombosis, or blood clots. Betrixaban, a U.S.Leer más Llamada en conferencia